Latest News and Press Releases
Want to stay updated on the latest news?
-
Active Biotechs årsstämma hölls den 10 maj 2012. I enlighet med styrelsens förslag beslöts att ingen utdelning skulle lämnas. I enlighet med valberedningens förslag omvaldes styrelseledamöterna...
-
The Annual General Meeting of Active Biotech was held on May 10, 2012. In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid. In accordance with the...
-
Laquinimod - submission of application for regulatory approval in the EU planned for second half of 2012 - Phase III data presented at the Annual Meeting of the American Academy of...
-
Laquinimod - registreringsansökan planeras inlämnas i EU andra halvåret 2012 - fas III-data presenterade på "64th Annual Meeting of the American Academy of Neurology"...
-
Active Biotechs årsredovisning för 2011 finns nu tillgänglig på www.activebiotech.com. Årsredovisningen kommer enbart att distribueras digitalt. Lund den 17 april 2012Active Biotech AB (publ) ...
-
Active Biotech's Annual Report 2011 (in Swedish) is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Lund, April 17, 2012 Active...
-
Styrelsen för Active Biotech AB (publ) har utfärdat kallelse till årsstämma, vilken kommer äga rum torsdagen den 10 maj 2012 klockan 17.00 på Edison Park, Emdalavägen 16 i Lund. Kallelsen, som...
-
The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place at 5 p.m. on Thursday, May 10, 2012, at Edison Park, Emdalavägen 16 in...
-
Fas III-studien ALLEGRO visar att laquinimod minskar antalet relapser per år, bromsar sjukdomsutvecklingen och minskar förlusten av hjärnvävnad Laquinimod uppvisar en fördelaktig säkerhets-...
-
Phase III ALLEGRO study results showed laquinimod reduced the annual rate of relapses, slowed the progression of disability, and decreased brain tissue loss Laquinimod was associated with...